trial

Clozapine-induced Hypersalivation - Feasibility Trial

NCTId NCT02613494
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 29 (actual)
Sponsored by Mersey Care NHS Trust
Primary completion 2017-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-01-25
Primary completion
2017-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
HyoscineGlycopyrrolate

Sponsors

Mersey Care NHS TrustLead Sponsor
University of ManchesterCollaborator
University of Central LancashireCollaborator
Manchester Mental Health & Social Care TrustCollaborator
Lancashire Care NHS Foundation TrustCollaborator

Investigators

1
Dr.Inti Qurashi, MDPrincipal Investigator

Sites

2 total
Preston, United KingdomLiverpool, United Kingdom

Linked catalysts

1
Clozapine-induced Hypersalivation - Feasibility Trial — primary completion2017-12-31

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE1,PHASE2
Primary Completion Date
2017-12-31
Status
COMPLETED
relationships
The graph out of here
drug
Hyoscine
drug
Glycopyrrolate
drug
lead_sponsor
Mersey Care NHS Trust
company
collaborator
University of Manchester
company
University of Central Lancashire
company
indication
Schizophrenia, Treatment-Resistant
indication
Sialorrhea
indication
Sialorrhea
indication
investigator
Dr.Inti Qurashi, MD
person